|
13 Jul 2021 |
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
|
|
13 Jul 2021 |
ExeVir's COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
|
|
13 Jul 2021 |
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
|
|
13 Jul 2021 |
Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
|
|
13 Jul 2021 |
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
|
|
13 Jul 2021 |
48Hour Discovery and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals
|
|
13 Jul 2021 |
Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19
|
|
13 Jul 2021 |
Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
|
|
13 Jul 2021 |
ReiThera Announces Preliminary Phase 2 Data from its COVID-19 Vaccine Candidate
|
|
13 Jul 2021 |
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
|
|
13 Jul 2021 |
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas
|
|
13 Jul 2021 |
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
|
|
13 Jul 2021 |
Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
|
|
13 Jul 2021 |
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
|
|
13 Jul 2021 |
Prothena and Novo Nordisk announce acquisition agreement for Prothena’s ATTR amyloidosis programme
|
|
13 Jul 2021 |
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
|
|
12 Jul 2021 |
Stem cell therapy company Amniotics raises SEK 60 million in First North IPO to advance lead candidate PulmoStem™ into clinic
|
|
12 Jul 2021 |
Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
|
|
11 Jul 2021 |
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
|
|
11 Jul 2021 |
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
|
